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Purpose: The purpose of this study was to evaluate the effect of platelet-rich fibrin (PRF) on the 
soft tissue wound healing and postoperative pain when it is used as an adjunct therapy for guided 
bone regeneration (GBR) procedures.  
  
Materials and Methods: Seven patients were randomly assigned to test group (GBR + PRF; 
n=5) and control group (GBR only; n=2), and soft tissue healing and pain levels were evaluated. 
Routine GBR procedures using dense polytetrafluoroethylene (dPTFE) membranes were 
performed for control group. For the test group, the liquid-form PRF was mixed with bone graft 
materials and PRF membranes were placed on top of the dPTFE membrane. Following surgery, 
patients in both groups were given a visual analog scale (100 mm) to use for rating their pain 
level every night for the next week. Post-operative appointments were scheduled at weeks 1, 2, 4, 
6, 8, 12, and 16. During the post-operative appointments, the soft tissue healings were evaluated. 
The present report follows patients for the first 6 weeks post-GBR surgery.  
 
Results: Patients in the test group showed a more rapid decline in self-reported pain during the 
first week after the surgery, with ratings for the test group being substantially lower than those 
for the control group. Whereas no membrane exposure was noted for either control patient, 
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exposure was noted for two of the five test patients during follow-up visits. In contrast to 
membrane exposure, evidence of gingival inflammation was noted in all patients. Similar to the 
findings for membrane exposure, abnormality in soft tissue consistency was noted for 
participants in the test group only, mainly in the exposure patients.  
 
Conclusion: The present study suggests that addition of PRF to GBR procedures may lower the 
postoperative pain level. But due to the small sample size, it was difficult to draw a conclusion 
on the effect of PRF on all of the outcomes especially the membrane exposure and other soft 
tissue parameters. After additional data are collected by the next investigator, we may be able to 
draw more definitive conclusions. The next report will also look at the bone quality and quantity 
in the histologic and radiographic analysis.   
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1.0  INTRODUCTION 
1.1 PLATELET-RICH FIBRIN 
Platelets are cytoplasmic fragments of approximately 2 μm in diameter of 
megakaryocytes which is formed in the bone marrow and survive between 7 and 10 days.1 
They have more than 30 bioactive proteins, many of which are important for hemostasis or 
tissue healing through the inflammation process. The following fundamental protein 
growth factors are actively secreted by platelets and commence wound healing processes: platelet-rich fibrin (PRF) including platelet derived growth factor (PDGF), transforming growth factor β (TGF-β), vascular endothelial growth factor (VEGF), epidermal growth 
factor (EGF), fibroblastic growth factor (FGF), connective tissue growth factor (CTGF), and 
insulin-like growth factor (IGF-1).2,3  
1.1.1 Platelet Concentrate Products  
Platelet concentrates are a relatively new form of biomaterials for regenerative 
procedures, which are widely used in medicine and dentistry. It is known that the 
regenerative potential of these concentrates derives not only from the previously 
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mentioned growth factor contents, but also from associated leukocytes, circulating 
progenitor cells, and cell adhesion molecules such as fibrin, fibronectin and vitronectin.4,5  
Two main types of autologous platelet concentrates are currently used in dentistry: platelet-rich plasma (PRP) and platelet-rich fibrin (PRF). As a first-generation platelet 
concentrate product, PRP was the first to be used as a therapeutic adjunct for oral and 
maxillofacial surgery in 1997 by Whitman et al.6 and thus has been more widely studied than the second-generation product, PRF. Since Choukroun and colleagues first published 
their work on PRF—initially in French (2001)7 and later in English (2006)8- 12—several 
comparison studies have demonstrated the advantages of PRF over PRP, which can be summarized as follows:2,13  
●          simplified preparation;  
●          no biochemical manipulation of blood; 
●          greater number of platelets; 
●          greater number of growth factors (GF); 
●          about 65% leukocyte contents whereas PRP has 0-50% leukocytes; 
●          more gradual release of GF; and 
●          stronger and more durable effect on proliferation and differentiation of 
osteoblasts. 
These characteristics of PRF will be compared to PRP in detail below for further 
understanding. 
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1.1.2 Superiority of PRF over PRP 
Simpler Preparation and manipulation. Dhurat and Sukesh (2014)3 described the 
PRP preparation protocol. Whole blood is drawn by venipuncture in acid citrate dextrose 
tubes and centrifuged using a soft spin for 10 minutes. The supernatant plasma layer on 
top of the tube is separated from the red blood cell layer and transferred to a new tube for 
second centrifugation at hard spin for another 10 minutes. The most platelet and leukocyte 
concentrate will settle in the bottom ⅓ of the tube. Therefore, by removing the upper ⅔, a 
provider gets the final product for PRP from the remaining bottom layer. (Figure 1). This 
layer is then activated by adding bovine thrombin or calcium before being applied to the 
surgical site. 
Unlike PRP preparation described above, PRF preparation only needs one 
centrifugation and does not need any additives either in the blood collecting tube or on the 
final product after centrifugation. 
According to the French group who invented PRF preparation procedure (Dohan et 
al., 2006),8 a blood sample is collected in 10-mL glass tubes without any anticoagulant 
additives. Anticoagulants are not needed for PRF because natural silica on the glass tube 
walls initiates the coagulation cascade.14 This natural silica does not represent a cytotoxic 
risk like the bovine thrombin used for PRP preparation.15 Without anticoagulants, the 
activation of platelets happens as soon as it comes in contact with the natural silica on the 
glass tube and the coagulation cascade initiates, which transforms highly concentrated 
fibrinogen into fibrin by the circulating thrombin. Therefore, a quick blood collection and 
immediate centrifugation is a key strategy for PRF preparation.8 
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FIGURE 1. Flow diagram describing preparation of platelet rich plasma (PRP). Figure 
reproduced from Dhurat R, Sukesh M. Principles and methods of preparation of platelet-rich 
plasma: A review and author’s perspective. J Cutan Aesthet Surg 2014;7(4):189-197. 3  
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After an immediate centrifugation at 3000 rpm (approximately 400g) for 10 
minutes, a dense fibrin clot is formed in the middle of the tube, between acellular plasma at 
the top and the red blood corpuscles at the bottom. This fibrin clot is then picked up from 
the tube and transferred to a flat sterile surface for a compression to obtain the final fibrin 
membrane.8,14 (Figure 2) 
  
FIGURE 2. (A) Blood processing with a centrifuge for PRF allows the composition of a 
structured fibrin clot in the middle of the tube (B), which easily makes resistant autologous fibrin 
membranes by driving out the serum from the clot (D). Figure and caption reproduced from 
Dohan DM, et al. Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part I. 
Technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 
2006;101(3):e37-44.8  
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Higher values of platelets, growth factors and leukocytes. A comparison study in 
20152 found a greater quantity of platelets and the growth factors PDGF, VEGF and TGF in 
PRF compared to PRP. Moreover, about 65% of white blood cells from the total blood 
sample become entrapped in the fibrin matrix after centrifugation in PRF, whereas less 
than 50% of white blood cells are concentrated in PRP. The authors of the study concluded 
that PRF membrane has a higher potential to more efficiently and effectively regulate the 
local immune response and with better feedback control of the inflammation. Clinically this 
leads to the better control of postoperative infections when the PRF is utilized in the 
surgical procedure. They also mentioned that three-dimensional PRF fibrin matrix 
conformation is optimized to start the neo-angiogenesis from rapid invasion by leukocytes, 
which contain the VEGF that acts as a potent vascular growth factor.2  
More gradual release of growth factors. An in vitro study,13 quantified the levels of platelet-derived growth factor AB (PDGF-AB) and transforming growth factor 1 (TGF-1) 
in PRP and PRF produced from human blood sample. These products were used to culture 
96-well plates of rat calvaria osteoblasts, with the biologic characteristics of osteoblasts 
being analyzed for 14 days. Results showed that both growth factors were released at the 
highest amounts on the first day in PRP followed by significantly decreased release later on. On the other hand, PRF released the highest amount of PDGF-AB at day 7 and of TGF-1 
at day 14. Further investigation on the cell mineralization revealed PRF treated osteoblasts 
reached peak mineralization at day 14, which was significantly higher than control and PRP 
treated cells. The authors of the study concluded that PRF is superior to PRP in terms of 
gradual release of growth factors and expression of more significant cell proliferation and 
differentiation of rat osteoblasts in vitro.13 The gradual growth factor release of PRF is 
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deemed due to the nature of fibrin matrix that biodegrade gradually, unlike the liquid form 
of PRP. According to Kawase et al.,16 it takes approximately 1 to 2 weeks for PRF 
membrane to completely resorb in vivo.  
1.1.3 Clinical Applications 
The efficacy of platelet concentrates on soft and hard tissue regeneration has been 
studied in diverse disciplines of dentistry including periodontics, endodontics, and oral and maxillofacial surgery. Applications include endodontic pulp regeneration, free gingival 
graft, connective tissue graft, surface treatment of implant for the stimulation of 
osseointegration, the treatment of peri-implantitis and intrabony defects, socket preservation, maxillary sinus augmentation, treatment of orofacial clefts, medication-
related osteonecrosis of the jaw (MRONJ), and guided bone regeneration (GBR).17-41 
1. Endodontics 
Endodontic treatment of necrotic immature teeth is not always easy due to thin 
dentinal walls that frequently fracture. Calcium hydroxide formally had been widely used, 
but its long-term use reduced micro-hardness of the dentin by disruption of the links 
between collagen fibers and hydroxyapatite crystals, which increased risk of fracture. A 
newer material, mineral trioxide aggregate (MTA), was introduced but fracture is still a 
challenging issue due to relatively unchanged dimension of thickness of dentinal walls and 
length of the roots after the treatment. As several studies have evaluated feasibility of 
regenerative procedures to overcome these problems, platelet concentrate products have 
been recommended as a potential scaffold.17,18  
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Keswani and colleagues evaluated seventy children who needed pulpotomy with 
incomplete root development for 24 months after treatment with MTA (control) and PRF 
(test).19 They reported that clinically and radiographically evaluated success was not 
significantly different between the groups. But at the 24-month follow up, radiographic 
evaluation revealed that complete apical closure was observed in 88.8% of the PRF group 
and 80.07% of roots in the MTA group. The authors concluded PRF is a good alternative to 
MTA in pulpotomy procedures of permanent teeth with incomplete root development. 
2. Palatal wound after autogenous soft tissue graft harvest 
When 40 wounds were compared between PRF (N=20) and gelatin (N=20) sponge, 
the PRF group showed a significantly faster complete re-epithelialization of the palatal 
wound (P <0.001).20 At the end of week 2, 35% of the test group patients showed complete re-epithelialization whereas only 10% of the gelatin sponge group showed complete 
healing. At the end of week 3, all palatal wounds in the test group epithelialized completely, 
whereas only 25% of the control group showed complete re-epithelialization. PRF patients 
also reported significantly less discomfort and took a significantly lower dose of analgesics 
(P = 0.02). The authors concluded that PRF significantly accelerates palatal wound healing 
and reduces patients’ morbidity.  
3. Coronally advanced flap 
A randomized, split-mouth, controlled study compared PRF membrane (test) with 
subepithelial connective tissue graft (SCTG; control) for a modified coronally advanced flap 
(MCAF) in treatment of a total of 60 defects in 20 patients with Miller Class I and II bilateral 
multiple gingival recessions.21 The percentage of root coverage was significantly greater in 
 9 
the control group (84%) relative to the test group (77%). By comparison, complete root 
coverage differed only marginally between the two groups (60% and 50% in control and 
test groups, respectively). Keratinized tissue width (KTW) and gingival thickness (GT) significantly increased in both groups at 6 months after the procedures; KTW was 
significantly wider in the control group whereas GT was significantly thicker in the test 
group. Additionally, PRF group showed significant decrease in patients’ self-reported 
postoperative discomfort (visual analog scale) compared to SCTG group. The author 
concluded that the PRF is a valid alternative to SCTG to treat localized gingival recessions 
with an additional benefit of giving less discomfort during the healing period.21 
Another study compared the addition of PRF membrane for modified coronally 
advanced flap (MCAF) (test) with MCAF only (control).22 The study recruited twenty 
subjects who had multiple Miller class I and II multiple gingival recessions on both sides of 
the mouth. At 6 months, 74.6% of the treated sites showed complete root coverage in 
control group, whereas only 52.2% of the treated sites showed completed root coverage in 
the test group. But increase of gingival thickness in the test group (1.1 ± 0.3 mm → 1.4 ± 0.5 
mm) was statistically significant when compared to the control group (1.1 ± 0.3 mm → 1.1 ± 0.3 mm). The authors concluded that addition of PRF membrane under the MCAF is less 
predictable for root coverage but more predictable for gain in gingival thickness at 6 months. 
A recent meta-analysis study based on six previous studies followed up for ≥6 
months, however, reported that the use of PRF membranes did not give any additional 
benefits compared to the other treatment modalities in terms of the root coverage, 
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keratinized tissue width, or clinical attachment level in Miller Class I and II gingival recessions.23 
4. Intrabony defects 
A study of chronic periodontitis patients evaluated the efficacy of PRF on treatment of a total of fifty-six 3-wall periodontal intrabony defects.24 The test group received PRF 
and open flap debridement and the control group received open flap debridement only. 
Probing depth (PD) and periodontal attachment level (PAL) were recorded at baseline and 
9 months postoperatively. Results showed that the PRF group demonstrated greater PD 
reduction (4.55 ± 1.87 mm) and CAL gain (3.31 ± 1.76) than the control group (3.21 ± 1.64 
mm and 2.77 ± 1.44 mm, respectively). They also compared the bone fill using the baseline 
and 9 month postoperative radiographs, and reported a significantly greater percentage of 
mean bone fill in PRF group (48.26% ± 5.72%) compared to the control group (1.80% ± 
1.56%). The authors concluded that addition of PRF was beneficial for treatment of 
intrabony defects. 
Another study investigated the effectiveness of PRF in the treatment of intrabony 
defects with open flap debridement (OFD) only (control) or with PRF (test), and reported 
similar findings.25 The results revealed that the test group was superior to the control 
group on all the clinical and radiographic parameters that they evaluated and the 
difference was statistically significant. 
The above studies proved the effectiveness of PRF on intrabony defects when it is 
used with open flap debridement. However, PRF membrane resorption time is 
approximately 1-2 weeks,16 which therefore would not serve as a good scaffold if one is 
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expecting to gain some bone regeneration. A split-mouth study was then performed to 
compare PRF only with PRF with bone graft material26 and investigate the effect of the 
actual bone particulate when it is used with PRF. Seventeen paired intrabony defects were 
treated with PRF only on one site of the mouth (PRF) and PRF with bovine porous bone 
mineral (PRF-BPBM) on the other site of the mouth. Re-entry surgeries were performed at 
6 months. Results showed that PRF treatment improved the defect conditions on defect fill, 
PD reduction and CAL gain, but PRF-BPBM treatment improved more significantly as 
compared to the PRF only group. The authors of the study concluded that PRF can be used 
to treat periodontal intrabony defects, and one can expect even more significant effect by 
adding BPBM to PRF. 
5. Socket preservation 
Many socket preservation studies evaluate the effectiveness of PRF treatment on 
soft tissue healing, bone fill and discomfort and pain level following third molar extractions.27- 33 Currently there is mixed evidence on the effect of PRF in socket 
preservation, especially post-extraction pain. One of the impacted third molar extraction 
studies failed to show any beneficial effect of PRF on pain relief, 27 but some other studies 
suggested that surgical removal of impacted third molar with PRF significantly reduced not 
only the pain but also the other postoperative complications such as swelling and trismus, 
and it promoted soft tissue wound healing after tooth extraction.27-33  
Another possible complication exists when the impacted mandibular third molar is 
extracted; a delayed compromised healing causing distal bone loss and prolonged 
sensitivity due to root exposure or increased probing depth.31 Kumar and colleagues 
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evaluated the efficacy of PRF treatment on probing depth after impacted third molar extractions.31 Results showed that the application of PRF led to a larger average decrease in postoperative pocket depth at 3 months relative to treatment without PRF (PRF, 5.94 mm 
to 3.40 mm; control 6.09 mm to 4.78 mm). Results also indicated that pain, swelling, and 
trismus on day 1 postoperative were significantly less in the PRF group compared with the control group. The authors additionally reported that bone density scores at 3 months follow-up were higher in the PRF group than in the control group, even though the 
difference was not statistically significant. 
A different split-mouth study published in 201230 reported that PRF was 
significantly effective for both soft and hard tissue regeneration. Twenty patients who need 
bilateral mandibular third molar extractions were evaluated after PRF clot was placed in 
the socket. Soft tissue healing and bone regeneration were evaluated for 3 months. Soft 
tissue healing was significantly superior in PRF group based on the soft tissue healing index 
by Landry, Turnbull and Howley.34 At the 4 week postoperative radiographic evaluation, it 
was noted that trabecular bone formation started earlier in the PRF site as compared to the 
counterpart on the other side of mouth. At 3 months, postoperative radiographic 
evaluation of bone density showed that the grey level value in the PRF site was significantly 
higher than the control sites. The authors concluded that PRF significantly improved soft 
tissue healing, bone regeneration and bone density after the extraction sockets. 
6. Sinus lift 
Seventy-two maxillary sinus elevation grafting procedures using either Bio-Oss® 
and PRF (test group) or Bio-Oss® only (control) were followed up with bone core 
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harvesting at the time of implant placement surgery for histologic evaluation at day 106, 
120 and 150.35 The PRF clot was obtained, with part of it being used as a filling material in 
a form of “amorphous PRF” to be placed inside the sinus, and the rest flattened to make 
fibrin membrane out of it to be transferred onto Schneiderian membrane. 
The results revealed that bone maturation time was decreased with the use of PRF 
from the average healing time of 120-150 days as noted in previous literature for optimal 
bone regeneration,36,37 to 106 days—a reduction of 30%. At 106 days, it was already 
possible to place the implants with good primary stability, though without functional 
loading. The authors suggested that the gelatinous consistency of PRF made the clot 
stability better and the fibrin membrane created a natural “barrier effect” on the bone 
breaches opened in the surgical site. 
7. Orofacial clefts 
Twenty-four patients with unilateral alveolar cleft were evaluated after bone 
reconstruction with PRF and autogenous anterior iliac crest bone graft (test) and 
autogenous bone graft alone (control).38 Bone quality and quantity were assessed with 
computed tomography at 6 months postoperatively. The newly formed bone quantity was 
significantly superior in the PRF group (mean 82.6% ± 3.9%) compared to the control 
group (mean 68.4% ± 6.7%). The newly formed bone density (quality) was inferior in the 
PRF group than the control group, but the difference was not statistically significant. The 
authors concluded that addition of PRF in alveolar cleft reconstruction improved the 
volume of newly formed bone but was not significantly beneficial for bone density. 
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8. Medication-Related Osteonecrosis of the Jaw (MRONJ) or 
Osteoradionecrosis (ORN) 
According to a 2014 AAOMS position paper, a MRONJ diagnosis is established under 
these conditions: 1) Current or previous treatment with antiresorptive or antiangiogenic 
agents; 2) exposed bone or bone that can be probed through an intraoral or extraoral 
fistula(e) in the maxillofacial region that has persisted for more than eight weeks; and 3) no 
history of radiation therapy to, or obvious metastatic disease in the jaw bones.39 
ORN is diagnosed when the previously irradiated field shows the clinical findings of 
exposed necrotic bone without evidence of tumor recurrence. ORN can happen 
spontaneously but a lot of times is triggered by traumatic events such as tooth extraction or ill-fitting denture. 
Once MRONJ or ORN happens, it is very challenging to manage and usually only 
conservative treatments are rendered such as patient education, antibacterial mouth rinse, 
systemic antibiotics, and debridements depending on the severity of the condition.  
A recent case study evaluated PRF use to manage 3 patients with MRONJ and 4 
patients with ONJ. The treatment protocol was 1) debridement to bone with piezoelectric 
handpiece; 2) placement of PRF; and 3) primary closure without surgical flaps. Full soft 
tissue coverage was noted in 5 out of 7 patients at 2, 8, 10, 13 and 15 weeks respectively. 
The authors of the study concluded that PRF can be a good adjunct therapy for MRONJ or 
ORN. 40 
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9. Guided Bone Regeneration  
PRF is also used for guided bone regeneration procedure as an adjunct material to 
be mixed with the bone particulate as a liquid form or chopped membrane form, or as a 
sole or additional membrane as a fibrin membrane form. A case report evaluated the potential of platelet-rich fibrin (PRF) membranes on the bone and soft tissue regeneration.41 PRF membrane was placed on top of the combination of autogenous bone, 
bovine hydroxyapatite and PRF membrane that was cut into small pieces. They evaluated 
the surgical site radiographically for bone gain based on CBCT and clinically for soft tissue 
maturation 4 months after the surgery. The authors concluded that PRF was effective in 
terms of period of time for healing, gingival maturation and bone regeneration. 
In the present study, efficacy of PRF on guided bone regeneration (GBR) will be 
evaluated for soft tissue healing and pain. A more detailed discussion of the use of PRF in 
GBR procedures is presented below. 
1.2 GUIDED BONE REGENERATION 
As the demand for dental implant procedures increases, pre-implant bone 
augmentation procedures to increase the height and width of alveolar bone are also on the 
rise. In 1957, Murray and his team42 was one of the first research groups to come up with 
the idea of protecting bone defects from the overlying soft tissue by using a plastic cage 
barrier for new bone regeneration on decorticated dog femur. And since Dahlin and 
colleagues first introduced the successful bone regeneration by utilizing Teflon membrane 
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in mandible of rats in 1988,43 guided bone regeneration (GBR) has been developed into one 
of the most common bone augmentation procedures for the edentulous ridge. Many 
clinicians and researchers have tried with different materials and methods for GBR to 
achieve better results, but the main principles of GBR has not changed. 
According to “PASS” principles by Wang et al.,44 four major biologic principles need 
to be met: 
1.       Primary closure: Primary closure should be accomplished for an optimal 
environment away from bacterial infiltration and along with tension free closure for better 
chance to keep the site unexposed. 
2.       Angiogenesis: Adequate blood supply and angiogenesis are essential for bone 
regeneration, with decortication if one thinks it is beneficial for better blood supply, though 
it is controversial. 
3.       Space creating/maintenance: Space needs to be created and maintained for bone 
to form while unwanted epithelial and connective tissue cells are excluded. Prevention of 
membrane collapse is also important, especially for higher amounts of bone regeneration. 
4.       Stability of wound: Stabilizing the blood clot underneath the membrane is an 
important key because this initial blood clot has ample amount of cytokines, growth 
factors, and signaling molecules for initial healing and this clot is the precursor of granulation tissue which eventually turns into bone.  
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1.2.1 Membrane Types 
There are two main types of membranes, resorbable and non-resorbable, and their 
subgroups depending on the source and processing method. 
For a list of typical commercially available membranes, please refer to the 
publication by Rakhmatia et al.45  
Collagen membranes are made of natural source from bovine, porcine or human, 
while polyglycolic acid/polylactic acid (PGA/PLA) membranes are made of synthetic 
aliphatic polyesters. Resorbable membrane does not require a second surgery for removal, 
but space maintenance has been a main issue due to rapid degradation and flexibility. 
Cross-linking techniques are used to overcome the rapid degradation, but some fixatives 
used to treat the membrane for this feature such as glutaraldehyde are known to be not completely cytotoxic free.46 A new technique was recently introduced by Urban et al.47 to 
overcome this drawback of the resorbable membrane by tacking the stretched native 
collagen resorbable membrane to stabilize and protect the particulate bone graft inside 
until it completes initial graft maturation.47 
Non-resorbable membranes including titanium mesh, ePTFE (expanded 
polytetrafluoroethylene) and dPTFE (high-density polytetrafluoroethylene) are mainly 
used in current dentistry. ePTFE was first developed in 1969 and became the standard in 
bone regeneration in early 1990s but discontinued for dental use once dPTFE came out in 
1993 to enhance the strength of ePTFE and make up for the weakness of it.45 
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Premature membrane exposure during initial healing with non-resorbable 
membranes is one of the most common complications of regenerative procedures48 and 
immediate removal of membrane was necessary to prevent bacterial infiltration to the 
underlying bone graft through the pores of the ePTFE since its pore sizes are bigger (0.5-30 
microns) than most of the oral bacteria (approximately 0.2-10 microns).45 On the other 
hand, dPTFE has smaller pore sizes (0.2-0.3 microns) to prevent bacterial passing through, 
so the manufacturers claim that the membranes are not required to be removed even with 
exposure, as long as the exposure is not extending to the edge of the membrane.45 Some 
studies reported that food and bacteria were completely blocked even when the soft tissue 
dehiscence exist to cause membrane exposure, so one can still leave the membrane as 
exposed. 
1.2.2 Membrane Exposure 
In a study involving 102 guided tissue regeneration surgeries,49 the average time for 
Gore-tex membrane exposure was 16.2 days. Membrane exposure usually happens during 
the initial healing phase prior to soft tissue maturation; thus if membrane exposure can be 
prevented during the initial healing phase, more desirable outcomes are expected. 
In a meta-analysis conducted by Machtei et al.,50 the overall incidence of membrane 
exposure in GBR procedures was 60% with either resorbable or non-resorbable membrane 
and this exposure resulted in a significant decrease in the amount of new bone regeneration. 
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Further evidence by Simion et al.51 quantified the effect of e-PTFE membrane 
exposure around implants and found that the desired level of bone was regenerated in 
96.6% of cases when membranes were completely covered by tissue flaps at the time of implant placement one-month post-extraction, while only 41.6% of cases gained the 
desired level of bone when membranes were left exposed after immediate implant placement. 
More recent studies show that bone regeneration is not affected by premature 
membrane exposure if d-PTFE barrier membrane is used.52,53 But according to multiple 
case reports, once membrane is exposed prematurely, even if bone still regenerates, 
clinicians may encounter multiple problems, such as compromised patient comfort level, 
additional office visits for closer follow-ups, additional surgical procedures to remove 
exposed membrane before implant placement when indicated.54- 56 Therefore, membrane 
exposure prevention should be attempted whenever it is possible. 
1.2.3 Can platelet concentrate products help prevent membrane exposure? 
In GBR procedures utilizing titanium mesh, the test group with titanium mesh in 
combination with PRP had no membrane exposure, whereas the control group had 28.5% 
exposure.57 Moreover, height and width of bone augmentation was significantly superior in 
the PRP group (3.5 ± 0.7 mm height and 4.1 ± 0.6 mm width) compared to control group 
(3.1 ± 0.8 mm height 3.7 ± 0.6 mm width).57 The author of this study concluded that 
addition of PRP to the GBR procedure when Ti-mesh is used as a membrane, it is beneficial 
to prevent complications such as mesh exposure and consequent graft failure. 
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1.3 PURPOSE OF STUDY 
The present study evaluates whether the addition of PRF to conventional GBR 
procedures has a beneficial effect on the following clinical outcomes: incidence of 
membrane exposure, incidence of suppuration at the graft site, soft tissue consistency, 
severity of soft tissue inflammation, and severity of postoperative pain. The evaluation on 
the quantity and quality of bone based on radiographic and histologic analysis will be 
discussed on the next part of the study. The null hypothesis for this whole research project 
is that there is no difference in clinical outcomes between GBR procedures with and 
without PRF treatment. 
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2.0  MATERIALS AND METHODS 
2.1 STUDY POPULATION 
Twenty patients requiring GBR prior to implant placement will be eventually 
enrolled in the study based on the inclusion and exclusion criteria outlined in Table1. Half 
of the group will be treated with GBR+PRF (test group) and half of the group will be treated 
with GBR alone (control group); randomization of patients will be conducted by the RAND 
function in Excel. In this particular study, A total of seven patients were recruited and five 
of the seven were assigned to the test group and two patients were assigned to the control 
group. When the projected sample size of 20 patients is obtained, half will have been 
assigned to the test group and half to the control group. A succeeding provider will 
continue to see more patients until all twenty patients are treated. 
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TABLE 1. Inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
• Age ≥18 years old 
• Bone deficiency from single or 
multiple missing teeth 
• Bone regeneration with xenograft 
(Bio-Oss®) 
• Treatment with non-resorbable 
membrane 
• Systemic diseases that compromise 
wound healing including but not 
limited to, history of IV 
bisphosphonate treatment, 
autoimmune disorders and 
uncontrolled diabetes mellitus 
• Pathology present near the site of 
the procedure 
• Allergy to Penicillin antibiotics 
• Contraindication to Ibuprofen use 
• Smoker status 
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2.2 PROCEDURES 
In both groups, Cone Beam Computed Tomography (CBCT) was taken prior to the 
surgery to obtain baseline bone information. All GBR procedures were performed by 
making a crestal incision with two buccal/facial vertical releasing incisions as needed and 
raising a full-thickness mucoperiosteal flap. An additional periosteal releasing incision was 
made for coronal flap advancement. For the test group only, the PRF products was 
prepared to obtain liquid-form PRF to mix with the particulate bone graft material and PRF 
membranes to cover the dPTFE membrane (see Table 2 and Figure 1A-D). 
TABLE 2. Brief outline of PRF protocol 
1. Blood is drawn and collected in 10mL collection tubes. Amount of blood drawn 
varies depending on the defect size from 2 tubes to 5 tubes in total. 2. Tubes are immediately centrifuged for 3 minutes for liquid-form PRF and 10 
minutes for PRF clot. 
3. The liquid-form PRF layer is extracted from the tube using a syringe and mixed 
with bone graft materials, and the PRF clot is taken out of the tubes and placed on the grid in the PRF BOX and covered with compressor for 5 minutes to form a thin 
flat PRF membrane. 4. The remaining bottom blood cell layer is disposed of according to OSHA guidelines. 
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For this study, one tube of blood was spun for 3 minutes to obtain liquid-form PRF. 
This liquid-form PRF was then mixed with the particulate bone (Bio-Oss®), and placed at 
the defect site. The mixture of bone graft and liquid-form PRF was covered with the non-
resorbable dPTFE membrane and the PRF membrane was placed above the dPTFE 
membrane, just beneath soft tissue periosteum. The mucoperiosteal flaps was then 
approximated using PTFE sutures to obtain tension-free primary closure. Postoperative 
appointments and oral hygiene instructions were scheduled in the dental office at weeks 1, 
2, 4, 6, 8, 12, 16 post-GBR surgery. All patients received the same antibiotic and analgesic 
medications, as well as instructions for their use while postoperative instructions are given 
at the end of the surgery. Sutures were removed at 4-week postoperative appointment.  
Patients were also provided with a visual analogue scale (VAS) on which to record 
their daily pain level for the first week post-GBR. Briefly, patients were instructed to 
indicate their current experience of pain by placing a vertical line along a 100-mm line 
wherein 0 indicates no pain and 100 indicates the worst pain the patient has ever 
experienced. This self-evaluation of postoperative pain was instructed to record in the 
evening, immediately before they go to the bed. Patients were also asked to provide the 
time of day and time interval since their last dose of analgesic medication. Clinical 
measurements and photographs were taken at baseline and each follow-up visit.  
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2.3 MEASURES 
2.3.1 Clinical parameters: 
• Membrane exposure measured in the longest dimension: 0mm, <3mm, 3-
5mm, 5-10mm, >10mm 
• Soft tissue inflammation according to a modified version of the Gingival 
Index (GI)58 
• Firm or boggy soft tissue consistency 
• Absence or presence of suppuration 
At 5 months post-GBR, a CBCT is planned to be taken on all patient groups and will 
be analyzed blindly for bone quantity and quality comparing to the baseline CBCT. At the 
time of implant placement at 6 months, a core of bone is planned to be trephined and 
analyzed histologically. Among a total of 7 patients who received GBR procedure, only 4 
patients have reached 5-month and 6-month point by the time the provider finishes the 
periodontics residency program. In present study, only soft tissue healing and pain will be 
evaluated, and analysis on CBCT and bone core sample histology will be investigated by a 
succeeding resident provider with more patient data. 
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3.0  RESULT 
Because of the small sample size, no formal statistical analyses were performed on 
the data collected from this study. Accordingly, only descriptive information (mean ± 
standard deviation) is presented here. 
3.1 SELF-REPORTED PAIN 
One patient was not compliant in returning the pain questionnaire report. Thus, 
data from only six patients were used to analyze the pain level. Figure 3 displays patients’ 
responses to the 7-day pain self-report, and a table that shows actual type of medications 
and time that medications were taken is attached in Appendix A. With a single exception 
(Subject 1004), patients in both groups reported moderate to severe pain on the first 
postoperative day (test, mean SD = 4.16 ± 3.10; control mean SD = 5.98 ± 1.87). However, 
patients in the test group showed a more rapid decline in self-reported pain, with ratings 
for the test group being substantially lower than those for the control group (test, mean SD 
= 0.65 ± 0.68; control, mean SD = 3.00 ± 1.41). While four patients showed consistently 
reducing pain level, two patients (Subject 1001 and 1007) reported increased level of pain 
in the middle of the week on day 4, and day 3 and 5, respectively.  
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FIGURE 3. Patient self-reported pain during the first week post-GBR surgery (n=6). 
Individual lines represent responses from a single patient  
3.2 SOFT-TISSUE HEALING 
Soft-tissue healing was examined across the first four postoperative study visits (+1 
week, +2 weeks, +4 weeks and +6 weeks) because all patients had been returned for at 
least four postoperative visits at the time of this writing. To summarize these data, scores on each of the four soft tissue measures were dichotomized to indicate whether patient 
examination revealed any membrane exposure, any abnormal color, boggy consistency 
indicative of poor healing or infection, or presence of suppuration, respectively, during any of the four postoperative study visits. Summary data for three of these measures are 
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displayed in Figures 2A, B, and C. Suppuration was not noted for any of the patients during 
any of the four visits. 
Unexpectedly, two patients in the test group displayed the evidence of membrane 
exposure during the six-weeks of follow up (Figure 2A). Whereas no exposure was noted 
for either control patient, moderate (3-5 mm) to severe (5-10 mm) exposure was noted for 
two of the five test patients (ID 1001 and ID 1002) during two or more follow-up visits. 
In contrast to membrane exposure, evidence of gingival inflammation was noted in 
all patients (Figure 2B). However, whereas control patients only experienced mild 
inflammation, two of the five test patients (ID 1002 and ID 1003) experienced moderate 
and/or severe inflammation.  
Similar to the findings for membrane exposure, abnormality in soft tissue 
consistency was noted for participants in the test group only (Figure 2C). In three of the 
four test patients with abnormal findings (ID 1001, ID 1003, and ID 1004), boggy 
consistency was noted during the one-week postoperative visit only. For the fourth patient 
(ID 1002), by comparison, boggy soft tissue consistency was noted during the one-, two-, six-week postoperative visits. 
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FIGURE 4. Abnormal soft-tissue findings.  A. Number of patients exhibiting membrane 
exposure during any of the four follow-up visits.  B. Number of patients exhibiting abnormal 
(mild, moderate, or severe) gingival inflammation during any of the four follow-up visits.  C. 
Number of patients exhibiting boggy tissue consistency during any of the four follow-up visits.   
 30 
4.0  DISCUSSION 
The purpose of the present study is to evaluate whether the addition of PRF is 
beneficial for conventional GBR procedures on the clinical outcomes including incidence of 
membrane exposure, incidence of suppuration at the graft site, gingival consistency, 
severity of gingival inflammation, and severity of postoperative pain during the healing phase. 
By comparison, the present study’s soft tissue findings are not consistent with 
previous research. Multiple soft tissue evaluations showed the benefit of PRF and other 
platelet concentrate products on wound healing for palatal wound management after 
autogenous soft tissue graft,Error! Bookmark not defined. tooth extraction,30,31 and GBR with 
titanium membrane.57 In the present study, two patients among five test group patients 
developed membrane exposures while no exposures were developed in two control group 
patients during the six-weeks of follow up. More gingival inflammation and boggy tissue 
consistency was noted in the test group as well.  
A couple of factors might explain why the present study did not find improvements 
in wound healing with PRF. Two of the five PRF group patients (ID 1001 and ID 1002) had 
either recent extraction (1-month prior) or simultaneous extractions when the GBR was 
performed, and only these two subjects showed the membrane exposure during the initial 
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healing among all seven patients.  The tension-free primary closure required relatively 
more involved soft tissue handling to advance the flap more coronally, and the surgical 
sites had significantly less keratinized tissue to handle during the procedure. Kfir et al.59 
evaluated the effect of immediate extraction and implant placement on the soft tissue and 
bone regeneration after the simultaneous GBR. They mentioned that complete soft tissue 
coverage of the extraction socket is difficult to obtain, and even if primary closure was 
accomplished after tooth extraction, it can result in early membrane exposure by epithelial 
dehiscence. They reported that out of the 15 patients, 7 patients had early membrane exposure, which was approximately 47% of the cases. 
Thus, if the study is redesigned, an additional exclusion might be added to the 
current exclusion criteria: simultaneous extractions. If both extraction and GBR were 
required for implant therapy, extraction should be performed prior to the GBR, and GBR 
procedure should not be initiated until the soft tissue remodeling is completed, which is up to 6 months.60 One of the test group patients (ID 1006) also received recent extractions, but 
it was 7 weeks prior to the GBR and did not show any membrane exposure. Our suggestion 
is to wait about 2 months after the extractions before the GBR procedure.  
Another assumption that may explain the membrane exposures among PRF group 
was the provider’s surgical skill. The first four out of seven patients were randomized to 
become test group and that is when the provider just started performing GBR procedures 
in the periodontics residency program. It is possible that the higher rate of compromised 
soft tissue healing and membrane exposure within test group is accounted for by the 
limited experience and lack of established techniques of the treatment provider, especially 
the first two subjects (ID 1001 and ID 1002) who showed the membrane exposure. 
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The soft tissue healing pattern looking at the soft tissue inflammation and 
consistency was slightly inferior in the test group patients. However, more inflammation 
and boggy tissue consistency have to be linked with the existence of membrane exposures 
because these findings were noted mainly in the membrane exposure patients. After the first follow-up, boggy consistency only appeared in the two membrane exposure patients. 
Tissue inflammation was a little more mixed, but moderate inflammation only turned up 
for one of the exposure patients and all the rest were mild inflammation.   
The present postoperative pain findings are consistent with the findings of multiple 
previous pain analyses that showed a positive effect of PRF on pain after the surgery.20,21,28-
33 Patients in the test group reported substantially less pain during the first week of healing 
after the GBR procedure compared to the control group. There were spikes in the middle of 
the week shown in Subject 1001 and 1007, and these patients are the only patients who 
took a combination of ibuprofen and hydrocodone/acetaminophen (see Appendix A). All 
the patients were instructed to take ibuprofen as regularly as possible at least for the first 3 
days postoperatively and also take hydrocodone/acetaminophen additionally only if 
ibuprofen was not enough to control the pain. These two patients freely took ibuprofen 
only, hydrocodone/acetaminophen only, or combination of two medications based on their 
subjective pain level. It could be explained that the inconsistent decrease of the pain level is 
due to the inconsistent administration of the drugs and different potency and effectiveness 
of two different drug modalities.  
One thing to note about this study is that by necessity it could not be blinded. 
Assuming it were possible to blind the subject, the pain result may have been different. 
Before the surgeries are started, all of the research patients hear and read the information 
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about PRF treatment with previous study showing potentially better and faster healing 
capacity and lesser postoperative pain. The better postoperative pain control in the test 
group that was shown in this study could have been the placebo effect because patients 
who received or did not receive the PRF already knew what they may expect.  
A limitation of this study was the sample size. Any patients who needed sinus lift at 
the time of GBR were excluded from the research recruitment because resorbable 
membrane was preferred for sinus lift. And many patients who need implant therapy 
already lost their teeth from previous periodontal disease with multiple contributing 
factors, which include smoking. Any smokers no matter how many cigarettes they smoke 
per day were excluded as well. Some patients were excluded because they were allergic to the medications that we needed to use, especially Penicillin. Due to the small sample size, it 
was difficult to generalize the treatment results.  
Another limitation will be the multiple treatment providers that will participate in 
this research project. When a succeeding resident continues the research until we recruit a 
total of 20 patients, it would be important to calibrate the new resident so all the 
procedures are performed in a similar fashion, in terms of the speed of the venipuncture, 
blood collection, and surgery itself, and the way to handle the materials and soft/hard 
tissue.  
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5.0  CONCLUSION 
One of the most important keys to prevent the membrane exposure after the GBR 
procedure is to follow the fundamental principles of the GBR which include 1) primary closure, 2) blood supply, 3) space maintenance and 4) stability of the wound. The addition 
of PRF treatment to properly performed GBR procedure may be beneficial for the wound 
healing and the pain control due to the healing potentials that PRF has. In the present 
study, it showed a trend that addition of PRF to GBR procedure lowers the postoperative 
pain level. But due to the small sample size, it was difficult to draw a conclusion on the 
effect of PRF on the membrane exposure and other soft tissue parameters. Once the 
study continues with a next investigator, with the additional data we may be able to 
draw more definitive conclusions. The next report will also look at the bone quality and 
quantity in the histologic and radiographic analysis.   
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APPENDIX A 
PATIENT REPORTS OF ANALGESIC MEDICATION USE DURING THE SEVEN DAYS FOLLOWING GBR SURGERY 
– RAW DATA 
ID time1 pmed1 pmed1t time2 pmed2 pmed2t time3 pmed3 pmed3t time4 pmed4 pmed4t time5 pmed5 pmed5t time6 pmed6 pmed6t time7 pmed7 pmed7t 
1001 22:15 HC/IB 22:15 23:15 HC/IB 23:30 23:20 HC 20:14 21:30 HC 21:30 0:15 IB 0:15 23:10 IB 19:30 22:00 IB 22:00 
1002 22:45 IB 17:30 22:00 IB 21:45 22:15 IB 22:00 22:00 IB 11:30 22:00 IB 7:30 22:00 IB 7:30 22:00 N   
1004 20:46 IB 13:00 8:00 IB 23:00 11:30 IB 11:00 10:00 IB 0:00 10:00 IB   11:00 IB     IB   
1005 22:00 IB 18:00 22:00 IB 18:00 22:00 IB 18:00 22:00 IB 18:00 22:00 IB 18:00 22:00 IB 18:00 22:00 IB 18:00 
1006 22:40 IB 22:40 23:00 IB 22:50 23:05 IB 21:50 23:00 IB 13:30 22:10 IB 20:20 22:36 IB 12:40 23:50 IB 19:40 
1007 21:30 HC/IB 21:30   HC/IB 21:55   HC 19:00   N     IB 20:30   IB 21:15   IB 23:30 
time() = time patient filled out form           
pmed() = type of pain medication patient took (HC=hydrocodone; IB=ibuprofen; HC/IB=combination; N=no medication)     
pmed()t = time patient took their last dose of medication 
filled cells = missing data  
bold type = control patient  
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